Showing results (691-700 of 727) with videos related to

Sort By:
Pageof 73
NPJ Precision Oncology|June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumorChristopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery|August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung CancerAnna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
Cancer Research|July 22, 2020
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR DependencyManav Gupta, Carla P Concepcion, Caroline G Fahey, et al.
JCO Precision Oncology|October 30, 2018
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung CancerIbiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Pageof 73